Journal Logo

Research Article: Observational Study

Genetic variant of MAML2 in the NOTCH signaling pathway and the risk of bladder cancer

A STROBE-compliant study

Shen, Yang MMeda,b; Lu, Qian MMeda,b; Ye, Hesong MDc; Deng, Zhonglei MDa,b; Ma, Long PhDa,b; Zhang, Qingling PhDa,b; Tang, Jingyuan MDa,b; Yuan, Lin MD, PhDa,b,∗

Section Editor(s): Lucarelli., Giuseppe

Author Information
doi: 10.1097/MD.0000000000018725

Abstract

1 Introduction

Bladder cancer remains one of the most common malignant cancers in the world, and it has high mortality and recurrence rates. In China, there are currently over 80,500 patients diagnosed with bladder cancer. Although the management of bladder cancer treatment has improved, the incidence and mortality still have not decreased in recent years.[1] Approximately 25% of diagnosed bladder cancer patients presenting with muscle invasion have poor outcomes despite radical surgery and chemotherapy and even radiotherapy.[2] As a previous study reported, risk factors for bladder cancer are complex and include acquired carcinogen exposure (such as tobacco smoking and occupational factors) and genetic variants.[3] Although cystoscopy remains a gold standard for bladder cancer diagnosis, its wide application is limited because of its invasiveness and high cost. In several years, plenty of methods and markers have been discovered and been attempted to predict and diagnose bladder cancer, such as routine systemic inflammatory markers,[4] neutrophil-to-lymphocyte ratio,[5] circulating tumor cells,[6] non-coding RNAs[7] and Glasgow Prognostic Score.[8] Therefore, a convenient way to early diagnose and manage bladder cancer and even recurrence after surgery is urgently needed.

The NOTCH pathway plays a leading role in cell fate.[9] It also has been studied in different malignant diseases and the Notch inhibitors possess anti-proliferative effects on cancer, thereby serving as a new treatment for cancer.[10] The NOTCH pathway itself seems to have a tumor suppressive function and inactivation promotes bladder cancer progression.[11] Disorder of the NOTCH pathway promotes cancer stem cell phenotype and epithelial-mesenchymal transition, thus increasing chemoresistance.[12] All of these factors provide a survival advantage for tumors and contribute to enhanced malignancy and a poor prognosis for patients. However, the genetic mechanism of how the NOTCH pathway is involved in bladder cancer remains unclear.

Single nucleotide polymorphisms (SNPs), as common genetic variations, occur in human evolution. Because of their changes in the structure of the genes, the biological functions of these genes will be influenced. Multiple studies demonstrate that many functional SNPs are related to the risks of bladder cancer and regulate genetic functions in pathways.[13–15] To the best of our knowledge, a systematic understanding of how SNPs implicated in the NOTCH signaling pathway contribute to bladder cancer development is still lacking. The aim of this study was to explore the underlying function and relationship of SNPs located in the NOTCH signaling pathway in bladder cancer.

2 Materials and methods

2.1 Study subjects

Firstly, the subject characteristics (580 cases and 1101 cancer-free controls) were updated according to previous association studies.[16,17] Briefly, a total of 580 bladder cancer patients were enrolled in Nanjing who was diagnosed by at least 2 pathologists. Meanwhile, local urologists collected the particular clinical information of each case. The 2004 WHO/ISUP classification of bladder cancer was used to confirm the tumor grade and stage. Additionally, 1101 controls were matched to the cases based on gender and age (±5 years). There was no genetical relationship between cases and controls. Besides, there were other 37 bladder cancer cases collected for the associated research. These 37 cases were also diagnosed by 2 pathologists and matched to the 580 cases population. The Institutional Review Board of the Affiliated Hospital of Nanjing University of Chinese Medicine approved this study.

2.2 SNP screening

The genes included in the NOTCH pathway were found using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway maps (www.kegg.jp/kegg/pathway.html). KEGG is an online database resource that helps researchers to explore mechanisms and functions in biological system research.

The schematic flow for selecting the candidate SNPs is shown in Figure 1. First, there were 36,960 SNPs selected in gene regions (including 2 kb upstream) based on the 1000 Genomes Project Chinese in Beijing (CHB) data (March 2012). Subsequently, a total of 5026 SNPs were extracted after quality control procedures were applied using the following criteria:

  • (1) minor allele frequency (MAF) ≥0.05,
  • (2) call rate >95%, and

Hardy-Weinberg equilibrium (HWE) ≥0.01.

Figure 1
Figure 1:
Flow chart for selecting single nucleotide polymorphisms in NOTCH pathway genes.

Second, CLUMP analysis was applied to filter the candidate SNPs with linkage disequilibrium (LD) r2 ≥ 0.8. Otherwise, we used RegulomeDB and SNPinfo Web Server to predict the SNP function. SNPinfo Web Server (https://snpinfo.niehs.nih.gov) is a set of web-based tools to predict the functional characteristics of SNPs. RegulomeDB (http://www.regulomedb.org/) is a database based on public datasets that is used to annotate SNPs and predict regulatory elements. Additionally, we retained SNPs with RegulomeDB scores greater than or equal to 3 and equipped with SNPinfo function.

2.3 SNP genotyping

Briefly, genomic DNA was extracted from EDTA-venous blood by the Qiagen Blood Kit (Qiagen). Illumina Human Omni Zhong Hua Bead Chips and Human Omni Express chips were chosen to perform genotyping for all samples. A selection process was established to filter the SNPs as follows: MAF ≥ 0.05, call rate >95% and HWE ≥ 0.01. Meanwhile, we performed a logistic regression analysis to calculate the outcomes and adjusted for gender, age and smoking status.

After confirming the candidate SNPs, we performed genotyping for 37 bladder cancer cases by ourselves (Supplementary Table 1, http://links.lww.com/MD/D578). DNA of 37 bladder cancer patients were extracted from EDTA-venous blood by the Qiagen Blood Kit (Qiagen) and genotyped by TaqMan allelic discrimination assay. A 384-well ABI 7900HT real-time PCR system (Applied Biosystems, Foster City, CA) and SDS 2.4 software (Applied Biosystems) were used to measure and analyze allelic discrimination. The primers and probes sequences are shown in Supplementary Table 2, http://links.lww.com/MD/D579.

2.4 RNA extraction, RT-PCR and expression quantitative trait locus (eQTL) analysis

RNA samples were isolated from 37 bladder tissues (paired to the above samples) by using Trizol reagent. PrimerScrpit RT Master Mix (Takara Bio Inc., DaLian, Co., Ltd) and RNA were mixed for reverse transcription and heated to 80°C for 5 seconds after 15 minutes at 37°C. Then, ddH2O was utilized to dilute the cDNA to one tenth. EvaGreen qPCR Master Mix (ABM Inc, Canada) and an ABI Prism 7900HT quantitative real-time PCR instrument were used for the reaction system, and GAPDH was used as a control. The primers are shown in Supplementary Table 2, http://links.lww.com/MD/D579. Combined with allelic discrimination and host gene expression, eQTLs were calculated for the candidate SNPs.

2.5 Bioinformatics analysis

We used the online software Xena (http://xena.ucsc.edu) to conduct a Kaplan–Meier analysis of overall survival with regard to bladder urothelial carcinoma (BLCA) target genes based on the TCGA database. Xena can be used to analyze and visualize functional genomics datasets based on public genomic or phenotypic datasets. In addition, UALCAN (http://ualcan.path.uab.edu/index.html), an interactive web tool for analyzing cancer transcriptome data, was used to analyze BLCA target gene expression based on major cancer stages.[18] Gene Expression Omnibus (GEO) was used to download extra datasets and to verify the target gene expression in bladder cancer, and we chose GSE42089,[19] GSE38265[20] and GSE37815,[21] which had particular clinical and phenotype information in this phase.

2.6 Statistical analysis

The goodness-of-fit χ2 test was performed to evaluate the HWE of the genotype frequencies in controls. Relationships between SNPs and bladder cancer susceptibility were assessed with odds ratios (ORs) and 95% confidence intervals (CIs) derived from multivariate logistic regression analysis with adjustment for gender and age. All statistical analyses were performed using R software (version 3.2.3). Two-sided P < .05 was considered significant.

3 Results

3.1 Characteristics of the study population

The frequency distributions of demographic characteristics in the case group and control group are shown in Table 1. There were no significant differences between cases and controls in gender and age (gender: P = .909; age: P = .753). Moreover, the smoking status was significantly different between the 2 groups (P < .001).

Table 1
Table 1:
Frequency distributions of selected variables between bladder cancer cases and controls.

3.2 Association of candidate SNPs and bladder cancer susceptibility

As shown in Figure 1, there were 47 candidate genes involved in the NOTCH signaling pathway. We screened 36,960 SNPs based on the 1000 Genomes Project (CHB) and obtained 5026 SNPs after the quality control procedures were applied. Moreover, two different web tools were used to predict the functional characteristics, and the interaction of their results was obtained (Supplementary Figure 1, http://links.lww.com/MD/D577). A total of 76 SNPs remained for genotyping and after quality control procedures were applied. After a logistic regression analysis adjusted for age, sex and smoking status, only rs7944701 and rs3760961 had P values below .05 (Table 2). Both SNPs were distributed in the intron region. In the additional study, we chose the rs7944701 T > C SNP located in MAML2 with the lowest P value (OR = 1.329, 95% CI = 1.115–1.583, P = .001).

Table 2
Table 2:
Association between the selected SNPs and bladder cancer risk in case-control study.

3.3 rs7944701 is an eQTL for MAML2

To explore the association between rs7944701 and MAML2 further, we analyzed the rs7944701 allelic discrimination and MAML2 expression in 37 bladder-adjacent normal tissues. When rs7944701 carried the C allele, MAML2was significantly differentially expressed (P = .034) (Fig. 2A). Therefore, rs7944701 is an eQTL for MAML2, and allelic changes would influence MAML2 expression even though it is an intronic variant.

Figure 2
Figure 2:
Expression of MAML2 in bladder cancer and normal tissues and eQTL analysis. (A) rs7944701 is an expression quantitative trait locus, for MAML2; (B) MAML2 expression was significantly different between normal tissues and tumor tissues based on bladder urothelial carcinoma; (C) The expression of MAML2 was compared based on GSE42089, GSE38265, and GSE37815. MAML2 = mastermind-like 2

3.4 Association of target genes with bladder cancer

SNP rs7944701 is located in the first intron of the MAML2 gene. We assessed the expression of the target gene MAML2 in bladder cancer. In the TCGA BLCA data, there were 412 tumor tissues and 19 normal tissues included. We observed that MAML2 expression in tumor tissues was clearly lower (P = 9 × 10−4; Fig. 2B). Besides, three GEO datasets, including non-tumor bladder tissues and bladder cancer tissues, were all human, and expression profiling was performed by array. We explored these data and found a remarkable statistical discrepancy in MAML2 expression between non-tumor controls and tumor cases. As shown in Figure 2C, MAML2 expression was higher in non-tumor tissues than in tumor tissues in GSE37815, GSE38265, and GSE42089 (P = .0127, P = 7.8 × 10−3and P = 1.7 × 10−3, respectively).

Subsequently, after dividing the BLCA cohort into two groups, high and low MAML2 expression, according to the median expression. The high MAML2 expression was correlated with lower overall survival (hazard ratio (HR) = 1.53, 95% CI = 1.29–1.82, P = .010; Fig. 3).

Figure 3
Figure 3:
Kaplan–Meier curve of overall survival in bladder cancer patients.

4 Discussion

The NOTCH pathway, as a highly conserved system, is a key element in the regulation of embryogenesis, nervous system development and function, and even tumorigenesis.[9] Rampias et al revealed that the NOTCH pathway was a new tumor suppressor in bladder cancer.[22] They unraveled that mutations in FGFR3 and RAS enriched in the NOTCH signaling pathway were associated with bladder cancer risk. Notably, mutations in the pathway could promote tumorigenesis by phosphorylating ERK1/2. Additionally, another study observed a remarkable association between bladder cancer and Notch2. Hayashi et al reported that the overexpression of Notch2 promoted tumor growth, invasion, and metastasis.[23] Notch 2 operates as an oncogene that promotes bladder cancer growth and metastasis through EMT, cell-cycle progression, and maintenance of stemness.[23] Notch2 activation correlated with adverse disease parameters and worse prognosis by immune histochemistry. Thus, inhibition of Notch2 is a rational novel treatment strategy for invasive bladder cancer. Another study had indicated that Notch1 and Notch2 have opposite effects on the progression of bladder cancer could give rise to potential therapeutic approaches aimed at blocking or restoring the Notch pathway.[24] According to these previous studies, the NOTCH pathway may regulate the incidence and progression of bladder cancer in an especially complex way. Nevertheless, these results are inconsistent. In this study, we comprehensively evaluated the association between 36,960 SNPs and 47 candidate NOTCH pathway genes. Based on the 1000 Genomes Project (CHB), we found several functional genetic variants associated with bladder cancer involved in the NOTCH pathway. In the following genotyping and statistical analysis, we found that 2 genetic variants, rs7944701 and rs3760961, had remarkable significance in bladder cancer. We focused on rs7944701 with the lowest P value in the additional study. Interestingly, the host gene MAML2 had a strong association with bladder cancer prognosis.

The SNP rs7944701 is located in MAML2, which is a member of the mastermind-like family of nuclear protein coding genes, defined as transcriptional coactivators of NOTCH receptors.[25] Through binding with the NOTCH intracellular domain, the MAML protein activates downstream genes of NOTCH and has high expression in the salivary gland, placenta, and skeletal muscle.[26] The MAML2 gene was also detected in hidradenoma and leukemia.[27,28] Some studies have reported that CRTC1/3-MAML2 protein fusion is a key promoting element in hidradenoma development, and MAML2 gene fluorescence in situ hybridization (FISH) could be a useful method to diagnose hidradenoma.[29] These results suggest that MAML2 or the MAML2 fusion protein is not a specificity marker. However, we found that few studies focused on the association between MAML2 and bladder cancer. In the present study, we were the first to find that MAML2 has significant differential expression in bladder cancer individuals.

To explore the connection between MAML2 and bladder cancer, we used UCSC Xena based on the TCGA bladder cancer data. These results indicated that patients with high expression of MAML2 had remarkably worse prognoses, suggesting that MAML2 acts as a promoter in the progression of bladder cancer. Relying on these findings, we revealed that MAML2 was a low expression gene in bladder cancer patients. MAML2 had an inhibitory function in the differentiation and proliferation processes of bladder cancer. Moreover, there were also significant differences in MAML2 expression between normal bladder tissues and bladder cancer tissues. In three GEO datasets, the expression of MAML2 was dramatically higher in normal tissues than in tumor tissues. Thus, we speculated a specific bond exists for identifying the expression of MAML2 to predict the progression of bladder cancer and even bladder cancer patients’ prognosis.

Additionally, we found that the strongest signal was represented by an intronic SNP called rs7944701, which was related to the susceptibility of bladder cancer in the Chinese population. Several studies have discovered many SNPs located in noncoding regions that are associated with cancer risks and progression. Jiang et al demonstrated that MYC enhancer with rs6983267-G allele could be activated and enhanced colorectal cancer cell proliferation.[30] Recent case reported by Tian et al also revealed that the intronic SNP, rs7959129, could facilitate a promoter-enhancer interaction and synergistically increase colorectal cancer risk.[31] Pattison et al showed that the intronic SNP rs8102137 was a strong genetic variant correlating with bladder cancer risk.[32] In their further research, they found that another intronic SNP, rs200996365, was in high LD with rs8102137 and was located within the KLF5 region, which is a transcriptional activator of CCNE1. These findings indicated that the high-risk intronic variant indirectly enhanced cell proliferation and the incidence of bladder cancer. Thus, we speculated that the intronic rs7944701 would affect its host gene MAML2 expression or function and would sequentially influence the regulation of the NOTCH pathway involved in bladder cancer. In order to prove our hypothesis, we performed an eQTL analysis for rs7944701. To the best of our knowledge, this study is the first eQTL analysis of rs7944701. The results illuminated that the rs7944701 C allele was negatively associated with MAML2 expression.

5 Conclusion

We demonstrated that the novel MAML2variantrs7944701, in the NOTCH/MAML2 signaling axis, was correlated with bladder cancer risk. For the first time, we revealed that rs7944701 was an eQTL for MAML2 and enhanced the susceptibility to bladder cancer. We also provided evidence that the TC/CC variant decreased the expression of MAML2. Simultaneously, MAML2 was expressed at significantly low levels in tumor tissue, and remarkably high expression levels indicated better overall survival. In the future, the exact mechanism of the NOTCH/MAML2 signaling axis in bladder cancer needs further exploration. In our research, in addition to rs7944701, there was another SNP with a strong signal, rs3760961, which has significant value in bladder cancer. Further studies are warranted to elucidate the mechanism of involvement of NOTCH pathway genes in bladder cancer development and carcinogenicity. Additionally, study of MAML family genes as functional mRNAs is also important in future research.

Acknowledgments

The authors are deeply grateful for Dr. LHT's and Dr. XJY's participation and support and Prof. Wang's guidance regarding this study.

Author contributions

Conceptualization: Jingyuan Tang.

Data curation: Yang Shen, Qian Lu, Hesong Ye.

Formal analysis: Yang Shen, Qian Lu, Hesong Ye, Zhonglei Deng, Long Ma.

Project administration: Lin Yuan.

Resources: Lin Yuan.

Supervision: Long Ma, Lin Yuan.

Validation: Qingling Zhang, Jingyuan Tang.

Visualization: Qian Lu.

Writing – original draft: Yang Shen.

Writing – review & editing: Yang Shen, Jingyuan Tang.

References

[1]. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32.
[2]. Chen Z, He A, Liu Y, et al. Recent development on synthetic biological devices treating bladder cancer. Synth Syst Biotechnol 2016;1:216–20.
[3]. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.
[4]. Cantiello F, Russo GI, Vartolomei MD, et al. Systemic inflammatory markers and oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Eur Urol Oncol 2018;1:403–10.
[5]. Vartolomei MD, Ferro M, Cantiello F, et al. Validation of neutrophil-to-lymphocyte ratio in a multi-institutional cohort of patients with T1G3 non-muscle-invasive bladder cancer. Clin Genitourin Cancer 2018;16:445–52.
[6]. Busetto GM, Ferro M, Del Giudice F, et al. The prognostic role of circulating tumor cells (CTC) in high-risk non-muscle-invasive bladder cancer. Clin Genitourin Cancer 2017;15:e661–6.
[7]. Terracciano D, Ferro M, Terreri S, et al. Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. Transl Res 2017;184:108–17.
[8]. Ferro M, De Cobelli O, Buonerba C, et al. Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical cystectomy: a multicenter experience. Medicine (Baltimore) 2015;94:e1861.
[9]. Conner SD. Regulation of notch signaling through intracellular transport. Int Rev Cell Mol Biol 2016;323:107–27.
[10]. Teoh SL, Das S. Notch signalling pathways and their importance in the treatment of cancers. Curr Drug Targets 2018;19:128–43.
[11]. Maraver A, Fernandez-Marcos PJ, Cash TP, et al. NOTCH pathway inactivation promotes bladder cancer progression. J Clin Invest 2015;125:824–30.
[12]. Sun W, Gaykalova DA, Ochs MF, et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Res 2014;74:1091–104.
[13]. Yuan L, Gu X, Shao J, et al. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol 2010;29:611–7.
[14]. Selinski S, Lehmann ML, Blaszkewicz M, et al. Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk. Arch Toxicol 2012;86:1369–78.
[15]. Verhaegh GW, Verkleij L, Vermeulen SH, et al. Polymorphisms in the H19 gene and the risk of bladder cancer. Eur Urol 2008;54:1118–26.
[16]. Wang M, Li Z, Chu H, et al. Genome-wide association study of bladder cancer in a Chinese cohort reveals a new susceptibility locus at 5q12.3. Cancer Res 2016;76:3277–84.
[17]. Xin J, Du M, Gu D, et al. Combinations of single nucleotide polymorphisms identified in genome-wide association studies determine risk for colorectal cancer. Int J Cancer 2019;145:2661–9.
[18]. Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017;19:649–58.
[19]. Zhou N, Singh K, Mir MC, et al. The investigational aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res 2013;19:1717–28.
[20]. Yoshioka N, Gros E, Li H-R, et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell 2013;13:246–54.
[21]. Kim YJ, Yoon HY, Kim JS, et al. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling. Int J Cancer Int J Cancer 2013;133:1135–42.
[22]. Rampias T, Vgenopoulou P, Avgeris M, et al. A new tumor suppressor role for the Notch pathway in bladder cancer. Nat Med 2014;20:1199–205.
[23]. Hayashi T, Gust KM, Wyatt AW, et al. Not all NOTCH is created equal: the oncogenic role of NOTCH2 in bladder cancer and its implications for targeted therapy. Clin Cancer Res 2016;22:2981–92.
[24]. Goriki A, Seiler R, Wyatt AW, et al. Unravelling disparate roles of NOTCH in bladder cancer. Nat Rev Urol 2018;15:345–57.
[25]. Wu L, Sun T, Kobayashi K, et al. Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol 2002;22:7688–700.
[26]. Bishop JA, Cowan ML, Shum CH, et al. MAML2 rearrangements in variant forms of mucoepidermoid carcinoma: ancillary diagnostic testing for the ciliated and Warthin-like variants. Am J Surg Pathol 2018;42:130–6.
[27]. Hsieh MS, Lien HC, Hua SF, et al. Clear cell hidradenoma of the breast with MAML2 gene rearrangement. Pathology 2017;49:84–7.
[28]. Menu E, Beaufils N, Usseglio F, et al. First case of B ALL with KMT2A-MAML2 rearrangement: a case report. BMC Cancer 2017;17:363.
[29]. Kuma Y, Yamada Y, Yamamoto H, et al. A novel fusion gene CRTC3-MAML2 in hidradenoma: histopathological significance. Hum Pathol 2017;70:55–61.
[30]. Chang J, Tian J, Yang Y, et al. A rare missense variant in TCF7L2 associates with colorectal cancer risk by interacting with a GWAS-identified regulatory variant in the MYC enhancer. Cancer Res 2018;78:5164–72.
[31]. Tian J, Chang J, Gong J, et al. Systematic functional interrogation of genes in GWAS loci identified ATF1 as a key driver in colorectal cancer modulated by a promoter-enhancer interaction. Am J Hum Genet 2019;105:29–47.
[32]. Pattison JM, Posternak V, Cole MD, et al. Factor KLF5 binds a cyclin E1 polymorphic intronic enhancer to confer increased bladder cancer risk. Mol Cancer Res 2016;14:1078–86.
Keywords:

bladder cancer; genetic variant; molecular epidemiology; NOTCH pathway; single nucleotide polymorphisms

Supplemental Digital Content

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.